ArQule Presents Clinical & Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium

From Startup ARQULE Link to Full Article: Three poster presentations demonstrate ARQ 751’s potential as both a monotherapy and in combination with other anti-cancer agents BURLINGTON, Mass.–(BUSINESS WIRE)–Nov. 16, 2018– ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations

Precision BioSciences Receives the 2018 SEBIO Venture Funding Award

From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-receives-the-2018-sebio-venture-funding-award/ DURHAM, North Carolina, USA, November 15, 2018 – Precision BioSciences announced today that it has been recognized as the recipient of the 2018 Southeast BIO (SEBIO) Venture Funding Award. Abid Ansari, Precision’s head of finance and operations, accepted the award at the

Sophiris Bio to Present at the Piper Jaffray Healthcare Conference

From Startup Sophiris Bio Link to Full Article: http://investor.sophirisbio.com/news-releases/news-release-details/sophiris-bio-present-piper-jaffray-healthcare-conference SAN DIEGO and VANCOUVER, British Columbia, Nov. 15, 2018 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today

Dermavant Appoints Todd Zavodnick as Chief Executive Officer

From Startup Dermavant Link to Full Article: https://dermavant.com/dermavant-appoints-todd-zavodnick-as-chief-executive-officer/ November 15, 2018 BASEL, Switzerland, Nov. 15, 2018 /PR Newswire/ — Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Todd Zavodnick as Chief Executive Officer. “It is an honor to join Dermavant at such an exciting time

Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen

From Startup Xeris Pharmaceuticals Link to Full Article: https://investors.xerispharma.com/news-releases/news-release-details/xeris-pharmaceuticals-releases-additional-phase-3-clinical-trial Positive efficacy and utility data presented during the 18th Annual Diabetes Technology Meeting CHICAGO, IL; November 12, 2018 – Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug

Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-and-maxcyte-enter-into-clinical-and-commercial-license-agreement/ Precision BioSciences is pleased to be working with MaxCyte. Read more about our clinical and commercial license agreement to use the MaxCyte electroporation system for non-viral delivery of genome editing tools during cell manufacturing in their press release below and here.

ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018

From Startup ARQULE Link to Full Article: BURLINGTON, Mass.–(BUSINESS WIRE)–Nov. 14, 2018– ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018,